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Introduction: Translocation of the anaplastic lymphoma kinase
(ALK) gene is involved in the tumorigenesis of a subset of non-small
cell lung carcinomas (NSCLCs) and identifies patients sensitive to
ALK inhibitors. ALK copy number changes and amplification, which
plays an oncogenic role in tumors such as neuroblastoma, are poorly
characterized in NSCLC. We aimed to study the prevalence of ALK
copy number changes and their correlation to ALK protein expres-
sion, epidermal growth factor receptor (EGFR) status, and clinico-
pathological data in patients with NSCLC.
Methods: ALK status was evaluated by fluorescence in situ hybrid-
ization (FISH). Specimens with ALK translocation were studied for
echinoderm microtubule-associated protein-like 4 (EML4), KIF5B,
and TFG status. ALK expression was assessed by immunohisto-
chemistry. EGFR gene and protein status were evaluated in adeno-
carcinomas. Survival analysis was performed.
Results: One hundred seven NSCLC cases were evaluated. There
were two cases of EML4-ALK translocation and one with an atypical
translocation of ALK. Both cases of EML4-ALK translocation had
ALK protein expression, whereas in the rest, ALK was undetected.
Eleven cases (10%) exhibited ALK amplification and 68 (63%) copy
number gains. There was an association between ALK amplification
and EGFR FISH positivity (p  0.0001) but not with prognosis. In
conclusion, EML4-ALK translocation is a rare event in NSCLC.
Conclusion: The study reveals a significant frequency of ALK
amplification and its association with EGFR FISH positivity in lung
adenocarcinomas. Based on these findings, a potential role of ALK
amplification in the response to ALK inhibitors alone or combined
with EGFR inhibitors in NSCLC merits further studies.
Key Words: ALK, Non-small cell lung cancer, Amplification,
Translocation, Polysomy.
(J Thorac Oncol. 2011;6: 21–27)
Lung cancer is the leading cause in the cancer-relateddeaths in developed countries.1 Although the prognosis of
this disease remains poor, some clinically relevant advances
have occurred in recent years. The identification of epidermal
growth factor receptor (EGFR) mutations and amplification
in a subset of patients with non-small cell lung cancer
(NSCLC), coupled with the development of EGFR tyrosine
kinase inhibitors, has opened new ways to treat this disease.2,3
Nevertheless, there is a need to find additional molecular
targets to further improve patients’ outcome.
Recently, the novel fusion transcript with transforming
activity, formed by the translocation of echinoderm microtu-
bule-associated protein-like 4 (EML4) (2p21) and anaplastic
lymphoma kinase (ALK) (2p23), has been described in a
subset of NSCLCs.4 ALK was originally involved in carcino-
genesis in anaplastic large cell lymphoma as part of a chro-
mosomal rearrangement as a fusion partner of nucleophos-
min.5 Other fusion partners to ALK have been described since
then and have been associated with other tumor types such as
myofibroblastic tumors, B-cell lymphomas, and squamous
cell carcinomas of the esophagus.6,7 The products of these
translocations are fusion proteins with constitutively acti-
vated ALK tyrosine kinase, which plays a role in carcinogen-
esis by the aberrant phosphorylation of multiple intracellular
substrates downstream of ALK-chimerical oncoproteins.8 In
preclinical models of activated ALK, specific ALK targeting
drugs inhibit cell proliferation and induce apoptosis in models
“addicted” to this genetic aberration.9
Moreover, the analysis of clinical specimens in a num-
ber of studies suggests that this fusion gene may define a
novel subclass of tumors within NSCLC characterized by
distinct clinicopathological features in both Western and
Asian populations.10–13 Nevertheless, other reports have de-
scribed cases that represent exceptions to this rule.14 There-
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fore, there are still many issues about the role of ALK in lung
cancer that remain to be determined. Most importantly, the
identification of EML4-ALK has provided clinicians with a
novel potential therapeutic target as demonstrated by the
favorable results of a phase I trial with a dual MET and ALK
small molecule inhibitor that has showed promising clinical
responses in patients harboring ALK translocations.15
Additional mechanisms of aberrant activation of
ALK have been described in neuroblastomas. In these
tumors, activating mutations and ALK amplification are the
underlying mechanisms for ALK-dependent tumorigene-
sis16–19 and are associated with a specific clinical pheno-
type in this disease. Nevertheless, copy number changes of
ALK and their significance are poorly characterized in
NSCLC and may represent an additional mechanism of
activation of ALK and, therefore, play a role in the carci-
nogenesis of a subset of lung tumors.
In this work, we sought to study the status of the ALK
gene by fluorescence in situ hybridization (FISH) on a pop-
ulation of white patients and correlate it with the status of
EGFR (mutations and copy number variations) in adenocar-
cinomas. We also correlated the genetic findings with clinical
outcome.
PATIENTS AND METHODS
Patient Population
The samples included in this study were obtained
from patients attending the Lung Cancer Unit in Hospital
del Mar for diagnosis and treatment. The only inclusion
criterion was the availability of tissue for biomarker stud-
ies. Clinical details of these patients were included in a
database. This project was approved by the local ethics
committee (CEIC-IMAS2009/3619/I).
Fluorescence In Situ Hybridization
Four-micrometer paraffin-embedded histologic sec-
tions were used for FISH analysis. To assess the genetic
status of EGFR and ALK, we used LSI EGFR/CEP7 and
break-apart ALK (2p23) probes (Abbott Molecular Inc., Des
Plaines, IL). To determine the fusion partner for ALK for
cases with ALK translocation, we examined previously iden-
tified fusion partners EML4 (2p23), KIF5B (10p11.22), and
TFG (3q12.2).20,21 Break-apart probes were designed using
bacterial artificial chromosome (BAC) clones selected from
the CHORI BAC/PAC resource (http://bacpac.chori.org):
centromeric EML4: pooled RP11-804P20 and RP11-413N9,
telomeric EML4: pooled RP11-798D22 and RP11-34L01;
centromeric KIF5B: pooled RP11-633K11 and RP11-281A19
in spectrum Red, telomeric KIF5B pooled RP11-460H18 and
RP11-166N17; and centromeric TFG: pooled RP11-320C17
and RP11-423M9, telomeric TFG: pooled RP11-49H3 and
RP11-168G7. FISH was performed as described previously.22
Results were analyzed in a fluorescent microscope (Olympus,
BX51) using the Cytovision software (Applied Imaging,
Santa Clara, CA). A minimum of 50 nuclei was scored.
Patients were classified as EGFR positive/negative ac-
cording to criteria described in detail elsewhere.23 As criteria
for copy number aberrations of ALK has not been established,
we arbitrarily used the following cutoffs adapted from the
criteria established for EGFR and HER2 in lung cancer
specimens.23,24 Briefly, gain (including both low and high
genomic gain) was defined as a mean copy number of 3 to 5
fusion signals in 10% of cells and amplification as the
presence of 6 copies of ALK per cell in 10% of analyzed
cells. In cases where clusters were observed, we reported the
percentage of cells with clusters and considered amplified,
cases with 10% of ALK clusters. On cases with ALK
amplification, FISH with CEP2 (a centromeric alpha-satellite
specific for chromosome 2) was performed (Abbott Molecu-
lar Inc.) to exclude polysomy. Normal fusion ALK, EML4,
KIF5B, and TFG signals presented as an overlapping orange/
red and green (yellowish) signals. These probes were consid-
ered typically rearranged when separated green and orange/
red signals (at least by three times the signal diameter) were
identified and atypically rearranged when a single orange or
green signal was seen.
Immunohistochemistry for EGFR and ALK
Four micrometers serial sections of paraffin blocks
were used for the evaluation of EGFR and ALK done with the
DAKO Cytomation EGFR PharmDxTM and ALK (D5F3)
antibody (Cell Signaling, Danvers, MA), respectively. This
antibody for ALK is able to detect the wild type and truncated
proteins. Diaminobenzidine was used as the cromogen to
identify positive results. The scoring for EGFR IHC was done
considering staining intensity, as recommended by the man-
ufacturer, from negative: 0, no detectable staining; to 3,
strong and continuous membranous staining. For ALK expres-
sion scoring, the percent of cells was determined within each
staining intensity category 0 to 4, and a hybrid score (H score)
was calculated by the formula: % cells of 0 intensity(% cells
of 1 intensity 1)(% cells of 2 intensity 2)(% cells of
3 intensity  3)  (% cells of 4 intensity  4).25 We used the
NCI-H2228 ALK translocated cell line as a positive control for
ALK expression purchased from the American Type Culture
Collection (http://www.ATCC.org).26
EGFR Mutation Detection
DNA was extracted from macrodissected tumoral
paraffin-embedded tissue using the QIAamp Tissue Kit
(QIAGEN GMBH, Hilden, Germany) according to the
manufacturer’s protocol. Mutational analysis of exons 18
to 21 of the EGFR gene was performed by direct seq-
uencing using tumoral DNA with BigDye v3.1 following
the manufacturer’s instructions and analyzed on an
ABI3730XLSequencer (Applied Biosystems, Foster City, CA).
Primers were designed using the Primer Express software (Ap-
plied Biosystems) and are available on request.
Statistical Analysis
Statistical analysis was carried out with SPSS version
13.0 (SPSS, Inc., Chicago, IL). To analyze correlations be-
tween ALK status and clinical-pathologic variables and EGFR
status, we used the 2 test or Fisher’s exact test. Survival
analysis was performed by the Kaplan-Meier method. Curves
were compared by the log-rank test. All the statistical tests
were conducted at the two-sided 0.05 level of significance.
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RESULTS
Patients’ Characteristics
One hundred seven patients were included in this study.
Clinical-pathologic characteristics are detailed in Table 1.
Stage I patients are overrepresented because tissue availabil-
ity is higher in these surgical cases.
ALK Translocations
The results of the FISH analysis of ALK are listed in
Table 2. We found three cases with ALK gene translocation
(Figure 1). Table 3 lists the characteristics of the translocated
cases. Two cases showed a typical gene breakage signal of
ALK, and for these, the FISH signal for EML4 was also
aberrant, consistent with the translocation involving both
genes. The third translocated case showed an atypical rear-
rangement with a deletion of the 5 region of ALK in 70% of
cells. In this case, the EML4 signal was normal, suggesting
the existence of another fusion partner to ALK. We investi-
gated the presence of TFG and KIF5B and found no translo-
cation of these genes. Of note, this case was a combined
carcinoma with an area of adenocarcinoma and an area of
large cell neuroendocrine carcinoma (LCNEC), and the ALK
aberration was restricted to the LCNEC area. Both patients
with EML4-ALK translocation were elderly at diagnosis (70
years), one of them was a never smoker female with a
mucinous adenocarcinoma and the other was a heavy ex-
smoker male with a solid adenocarcinoma.
ALK Copy Number Gains and Amplification
In our series, 11 cases (10%) showed amplification of
ALK (Figure 2). Table 3 lists the characteristics of these
patients along with seven cases (7%) with a small percentage
of cells (10%) showing clusters. Within the samples with
amplification, five cases were adenocarcinomas, one was a
bronchioalveolar carcinoma, and five had squamous cell
histology. There was no statistical association between am-
plification and gender, age, smoking history, or histology. We
observed a significant association between the presence of
amplification and early stage (I–II) (p  0.04). Notably, 9 of
11 cases with amplification were surgical cases and two cases
with squamous histology showed locoregional and exclu-
sively lung dissemination, respectively. The greater tissue
availability in the surgical cases might perhaps allow detec-
tion of amplification in those specimens with a low percent-
age of positive cells.
We found ALK copy number gains in 63% of cases. In
the majority of these cases, gains were seen in a high
proportion of cells (50–95%). No statistically significant
association was found between ALK copy number gain and
any of the clinical or pathologic parameters analyzed.
ALK Protein Expression by
Immunohistochemistry
We analyzed the ALK protein expression by immuno-
histochemistry in 90 cases where tissue was available (in-
cluding all translocated and amplified cases). We observed
ALK expression in the two cases with a typical ALK trans-
location pattern that also showed a rearrangement of EML4
(Figure 3). The case with a loss of the centromeric probe was
negative by IHC. In the remaining specimens, ALK protein
expression was undetected with the assay used.
EGFR and ALK in Adenocarcinomas
EGFR protein expression (1 to 3) was seen in 45 of
64 patients (70%). Fifty-six patients were evaluated for
EGFR by FISH. Of these, 28 (50%) were FISH positive (15%
amplifications) and 28 (50%) negative. EGFR mutation status
was studied in 68 patients, and mutation on exons 18, 19, and
21 were found in one (2%), six (9%), and four (6%) patients,
respectively. These cases were characterized by the clinical
TABLE 1. Patients’ Characteristics (N: 107)
Median age, yr (range) 66 (40–85)
Gender
Females 25 (23%)
Males 82 (77%)
Smoking status
Never 16 (15%)
Former 39 (36%)
Current 52 (49%)
Performance status (ECOG)
0–1 98 (92%)
2–3 9 (8%)
Stage
I 49 (46%)
II 6 (6%)
III 25 (23%)
IV 27 (25%)
Histology
Adenocarcinomaa 69 (65%)
Squamous cell carcinoma 30 (28%)
NSCLC NOS 2 (2%)
LCC and BAC 6 (5%)
a Includes two cases of combined carcinomas (adenocarcinoma with large cell
neuroendocrine carcinoma).
NSCLC NOS, non-small cell lung cancer not otherwise specified; BAC, bronchioal-
veolar carcinoma (noninvasive tumor with lepidic spread); LCC, large cell carcinoma
(exclusion diagnosis for a poorly differentiated tumor with absence of adenocarcinoma,
squamous, or small cell component).
TABLE 2. ALK FISH Results
Histology ADC SCC
NSCLC
NOS
LCC and
BAC All
ALK FISH (N: 107)
Normal 10 6 1 1 18 (17%)
Gain 45 18 1 4 68 (63%)
Amplification or
10% clusters
11 6 0 1 18 (17%)
Translocation 3a 0 0 0 3 (3%)
a One case was a combined carcinoma: ADC  large cell neuroendocrine
carcinoma.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; NOS, not otherwise spec-
ified; LCC, large cell carcinoma; NSCLC, non-small cell lung carcinoma; BAC,
bronchioaveolar carcinoma; FISH, fluorescence in situ hybridization; ALK, anaplastic
lymphoma kinase.
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features typical of these patients subgroup (female, nonsmok-
ers). Regarding the association between EGFR status and
ALK, we found a statistically significant association between
ALK amplification and FISH positivity for EGFR (p value
0.001). No statistically significant association with EGFR
mutations or protein overexpression was observed (Supple-
mentary Table 1, http://links.lww.com/JTO/A38). Two of the
cases with ALK clusters in a low percentage of cells harbored
an EGFR mutation on exon 21. No EGFR mutations were
found in the patients with ALK translocations.
Survival Analysis
We sought to explore the potential impact on survival
of ALK aberrations. Median follow-up for the whole series
was 10.6 months (0.1–61.2). As the majority of patients with
ALK amplification or 10% of clusters were stage I patients,
we stratified all stage I patients according to ALK status in
two manners. First, we analyzed amplified (six patients with
ALK amplification) versus nonamplified (33 patients with
copy number gains, four with disomic tumors, and five
patients with10% clusters), excluding the patient with ALK
translocation. Second, as the definition of ALK amplification
we used is not validated and we had observed clusters in a
low proportion of cells, we grouped these patients with
amplification cases (N: 11) versus nonamplified patients (N:
37). Because of the low number of patients in each group, we
continued the analysis with the second approach (grouping
amplification with clusters). Median follow-up for stage I
patients was 11.5 months (1.2–37.2). Five patients within
the stage I subgroup received adjuvant chemotherapy,
three of them within the ALK amplified group and two of
them in the nonamplified group. Mean overall survival was
32.4 months and 28.6 months for patients with ALK
amplification(clusters) and for those without ALK ampli-
fication, respectively (median OS was not reached for
either group). This difference was not statistically signif-
icant (p  0.4) (survival curves as Supplementary Figure
1, http://links.lww.com/JTO/A39). All three cases with trans-
location were alive without disease progression at the timing
of writing this work. Interestingly, one of the patients with a
pathologically confirmed stage IV adenocarcinoma (pleural
metastases) harboring an EML4-ALK translocation is alive
after 5 years of follow-up.
FIGURE 1. A, Left (arrows): atypical anaplastic lymphoma kinase (ALK) rearrangement with deletion of 5 region of ALK (loss
of green-labeled probe centromeric to ALK). Right: normal echinoderm microtubule-associated protein-like 4 (EML4) fusion
pattern. B, Left (arrows): typical gene breakage signal of ALK (yellow wild-type allele, and single red and green probe signals
for the rearranged allele). Right (arrows): EML4 typical probe breakage.
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FIGURE 2. A, Anaplastic lymphoma kinase
(ALK) amplification (orange/green fusion
signals) in a cell with three copies of CEP2
(red signals). B, Polysomic cells from the
same amplified case showing 3 to 4 copies
of ALK and 3 to 4 copies of the chromo-
some 2 centromere.
FIGURE 3. Immunohistochemical staining
analysis of anaplastic lymphoma kinase
(ALK) protein expression. Pictures are at
40 magnification. A, Case with ALK over-
expression H score: 260. B, Case with ALK
overexpression H score: 80. Both cases cor-
respond to the tumors from patients with
echinoderm microtubule-associated protein-
like 4 (EML4)-ALK translocations by fluores-
cence in situ hybridization (FISH).
TABLE 3. Characteristics of Patients with ALK Aberrations
Patient ALK FISH
Percentage
Cells ALK IHC Gender Age (yr) Smoking Histology Stage
106 EML4-ALK 64 POS M 74 Former ADC pIA
997 EML4-ALK 66 POS F 72 Never ADC IV(Pl)
215 ?-ALK 70 NEG M 74 Current ADC pIIIB
1259 Amplified 15 NEG M 59 Current SCC IV(L)
495 Amplified 70 NEG F 73 Never ADC pIIIA
692 Amplified 86 NEG M 55 Current ADC pIA
1123 Amplified 20 NEG M 50 Current SCC pIIIB
956 Amplified 10 NEG M 53 Current ADC pIIB
806 Amplified 40 NEG M 71 Former SCC pIA
278 Amplified 90 NEG M 82 Former SCC IIIB
180 Amplified 80 NEG M 79 Former SCC pIA
1432 Amplified 90 NEG M 48 Current ADC pIA
1493 Amplified 22 NEG M 65 Current ADC pIB
524 Amplified 52 NEG F 53 Current BAC pIA
1370 Clusters 3 NEG M 66 Former ADC pIA
1328 Clusters 5 NEG F 70 Never ADC pIB
1119 Clusters 8 NEG M 54 Current ADC pIIIA
1062 Clusters 8 NEG M 77 Former SCC pIA
1024 Clusters 5 NEG M 59 Current ADC pIA
839 Clusters 7 NEG F 64 Never ADC pIA
246 Clusters 6 NEG M 51 Current ADC pIV(B)
M, male; F, female; ADC, adenocarcinoma; SCC, squamous cell carcinoma; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; ALK, anaplastic lymphoma
kinase.
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DISCUSSION
Lung cancer is a devastating disease, and the need of
developing better treatments is an urgent need for our pa-
tients. Targeted therapy strategies have recently demonstrated
the importance of selecting patients according to the biologic
characteristics of the tumors.27
The discovery of a new potentially relevant oncogenic
event in lung cancer, the EML4-ALK translocation, and the
development of ALK inhibitors with promising results in
preclinical models and early clinical trials provides the ratio-
nale for the comprehensive characterization of this new
genetic aberration in patients with lung cancer.
Our work confirms the low incidence (3%) of ALK
translocation in an unselected population of patients diag-
nosed with NSCLC. Both typical translocations involving
EML4 and ALK showed a good correlation to FISH and IHC.
Nevertheless, the atypically rearranged case was not detect-
able by IHC, probably resulting from a lack of protein
expression derived from this translocation. This stresses the
need of further characterizing these atypical translocations
and their predictive value for sensitivity to ALK inhibitors.
Moreover, the ability of IHC to detect the protein expression
in tumors harboring the typical EML4-ALK rearrangement
supports the use of IHC with this sensitive antibody as an
easy and inexpensive clinical tool for mass screening of
patients with advanced NSCLC for this particular rearrange-
ment. Regarding the clinical-pathologic characteristics of
patients with ALK translocations, our findings are in contrast
with previously reported ones, which associated ALK trans-
locations with nonsmokers and young age patients.11–13 The
patients in our series were elderly, two of them with a
smoking history and one had LCNEC histology, a distinct
subtype of lung tumor which has not previously been reported
harboring ALK aberrations. Globally, although the number of
patients with translocations is low and we lack the statistical
power to draw definitive conclusions, we believe that screen-
ing of this genetic aberration at this moment should include
the general population of patients with NSCLC, maybe ex-
cept for those with EGFR mutations that seem to be mutually
exclusive with ALK translocations.
Interestingly, we found an unexpectedly high preva-
lence of ALK gene amplifications and copy number gains in
NSCLC. This is the first study reporting such high frequency
of this genetic aberration. Other reports that have evaluated
large populations of patients with NSCLC by FISH have been
published. One of them screened more than 600 cases28 and
reported a prevalence of 0.5% of ALK amplification. More
recent works evaluating ALK gene status by FISH10,11 do not
report amplification in their series. These differences with our
findings may be explained, at least in part, by the fact that the
previous studies used tissue microarrays (TMAs) or small
biopsies from patients with advanced disease for FISH eval-
uation. Supporting this hypothesis, we observed that the
percentage of cells within the tumor containing the amplifi-
cation or clusters is frequently low, which may explain the
possibility of this genetic aberration being missed in a TMA
sample or in a small biopsy. Accordingly, we detected ALK
amplification or clusters in surgical specimens (except for
two cases) where more tissue is available for analysis. An-
other reason for the difficulty of detection of these alterations
on a TMA section is that the cells harboring amplification
were scattered within the specimen. Nevertheless, ALK am-
plification could also represent an early genetic event in a
subset of lung carcinomas. In neuroblastoma, focal high-level
amplification has been described as an oncogenic event and
selects cells sensitive to ALK inhibitors16,19,29. The clinical
significance of ALK amplifications and increased copy num-
ber is not known in lung cancer. The lack of ALK protein
expression by our immunohistochemical assay, recently val-
idated as a highly sensitive antibody for detection of ALK
translocated cases30 together with the low percentage of cells
with amplification in most cases, suggests that amplification
might not be a biologically relevant event or predict response
to ALK targeting molecules. Furthermore, ALK is contained
in regions already reported as copy number polymorphisms
(http://projects.tcag.ca/variation/). This could explain the
large percentage of cases with copy number gain in our
series. In addition, the association of EGFR FISH positivity
with ALK amplification may define a subset of cases with
more frequent aneuploidy as a result of genomic instability.
Nevertheless, lack of protein detection with this novel anti-
body in the cases with copy number gain and amplification
does not definitely rule out the potential benefit of ALK
inhibitors in this population, as demonstrated in colorectal
patients without EGFR protein expression that do respond to
therapeutic monoclonal antibodies targeting EGFR.31 More-
over, genetic alterations present initially in a small percentage
of the tumor cells have shown to have a relevant biologic role
in subsequent phases of disease (i.e., resistant to initial
targeted therapy).32 Future studies will be needed to see
whether high ALK gene copy number and/or amplification
represent important association to sensitivity to ALK fusion-
targeted therapies.
In summary, we confirm that ALK translocations are
infrequent in patients with NSCLC. Immunohistochemical
analysis optimally detects EML4-ALK translocations and may
represent a clinically easy way to screen patients with
NSCLC for this alteration. Copy number gains and amplifi-
cations are a frequent event in NSCLC and ALK amplification
typically coexists with EGFR amplification. Although these
findings lack prognostic significance in our series, our results
pave the way to study the predictive role of ALK amplifica-
tion in NSCLC to potentially expand the spectrum of patients
that benefit from ALK inhibitors, alone or combined with
EGFR inhibitors.
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